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Introduction 
Over recent decades, antimicrobial resistance (AMR) has emerged as an enormous global issue. The 
rise in observed AMR bacteria can be attributed to the continuous overuse of antimicrobial therapies, 
not limited to healthcare but within a wide range of areas including in the veterinary services and 
agriculture.1 The problems with the overuse of antibiotics has been coupled with the lack of new 
antibiotic therapies. A number of pharmaceutical companies have abandoned research in the antibiotic 
field which has led to a lack of compounds able to effectively treat AMR bacteria.2 The continual over 
reliance placed upon antibiotics, along with a better infrastructure in society has led to geographical 
barriers no longer being an issue. This has resulted in the unrestricted movement of people, products 
and their microbial counterparts. Coinciding with this increase in movement has been the evolution of 
bacteria, which has allowed genes coding for antimicrobial resistance to be developed, shared and 
expressed by a number of different bacterial species. Once a resistance gene is produced, it is able to 
be transferred to other bacteria (both of the same and different genus) by horizontal gene transfer, 
therefore the potential to spread through the bacterial population is high.3 The result has been specific 
antimicrobial agents becoming ineffective and therefore impractical against certain bacterial strains.4 
In light of this, emphasis must be placed on the development of alternative antimicrobial agents in order 
 
to reduce the transmission of microbial agents and the burden placed upon conventional (antibiotic) 
therapies. 
Antimicrobial resistance is an issue within a wide range of infectious organisms. The 
“ESKAPE” pathogens include Enterococcus spp., Staphylococcus aureus, Klebsiella pneumoniae, 
Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp. These pathogens 
demonstrate high levels of multidrug resistance, and are responsible for a substantial percentage of 
nosocomial infections.5 The magnitude of this worldwide problem and the impact of AMR on human 
health, results in increased costs for the health-care sector. Further, the wider societal impact of such 
infections are of key concerns for governments. A report by the World Health Organisation (WHO) 
reported than an average of 8.7 % of hospital patients had nosocomial infections. The costs associated 
with this include an increased length of stay for infected patients, the increased use of drugs, additional 
laboratory costs, possibility of the need for isolation and increased morbidity and mortality rates. Since 
the issues associated with AMR include a number of areas outside the health sector, WHO estimated 
over 10 years ago that this phenomenon would result in a fall in real gross domestic product (GDP) of 
0.4 % to 1.6 % (which is equivalent to several billions of today’s dollars)6. Being a complex global 
public health challenge, no single or simple strategy will suffice to fully contain the emergence and 
spread of nosocomial and community acquired infectious organisms that become resistant to available 
antimicrobial drugs.  
Within nature, cells living freely in bulk solution usually become attached to a surface, and if 
retained, can then form a biofilm. A biofilm is a matrix-enclosed bacterial populations that are attached 
to a surface or an interface. Biofilms demonstrate a wide array of resistance mechanisms, including 
persistent dormant cells, hyper-mutability, quorum sensing and efflux pumps making them extremely 
tolerant / resistant to antibiotics and antimicrobials and thus greater antimicrobial resistance has been 
demonstrated in biofilms when compared to planktonic cells.7,8 Thus, there is a need for advanced 
antimicrobial surfaces to be developed. A range of 2D-nanomaterials that may be exploited is 
antimicrobial surface coatings, which could be used in areas with a population that is of increased risk 
of potential microbial / bacterial transfer, e.g. nosocomial settings. These include the carbon based 
materials such as graphite, graphite oxide, reduced graphite oxide, graphene, graphene oxide and 
 
reduced graphene oxide and non-carbon based materials for example boron nitrite, tungsten diselenide 
and molybdenum disulphide. 
 
Carbon-Based Nanomaterials 
The graphite and graphene derivatives have specific definitions (Table 1). There are a number of 
graphite and graphene derivatives (Table 2) that have been used in nanoparticulate and 2D form to 
determine their antimicrobial activity. 
Table 1. Definitions of the graphene / graphite derivatives   
Graphite / Graphene Type Definition 
Graphite In graphite, adjacent graphene layers overlap due 
to pz orbitals, producing bulk graphite.9 
Graphite oxide Graphite oxide refers to graphite with functional 
groups containing oxygen attached. It is prepared 
by treating graphite with strong aqueous 
oxidizing agents.10 
Reduced graphite oxide Reduced graphite oxide is produced by reducing 
graphite oxide, thereby removing attached 
oxygenated groups, allowing the honeycomb 
lattice to be achieved – which restores 
electrochemical properties.11 
Graphene Graphene sheets comprise of a 2D layer of sp2-
hybridized carbon atoms, arranged in a 
hexagonal (honeycomb) lattice.9 
Graphene oxide Graphene oxide refers to single-atom layers of 
carbon (graphene) with functional groups 
containing oxygen attached. The oxygen groups 
allow the molecular to become polar and 
therefore soluble.12 
Reduced graphene oxide In order to create reduced graphene oxide, 
graphene oxide can be reduced, often by thermal 
mechanisms allowing for the removal of attached 
oxygenated groups.12 
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Graphite is one of the oldest and most widely used of the carbon-based materials.30 Graphite is routinely 
used as a starting material in the production of a variety of carbon-based nanomaterials including 
fullerenes, nanodiamonds, single and multi-walled nanotubes and the synthesis of graphene.31 Graphite 
has been used in a variety of biomedical applications32, 33 including drug delivery,34, 35, 36 photothermal 
anticancer activity37, 38, 39, biosensors, biofunctionalisation34 disease diagnostics40, 41, 42  and antimicrobial 
therapies.43 
The antimicrobial activity of graphite has been demonstrated, whereby the interaction between 
graphite nanoplatelets and Pseudomonas aeruginosa (which can cause chronic infections in the lungs 
of patients with cystic fibrosis) was investigated. The results of a bacterial cell viability assay, 
performed after 5 h of incubation with graphite nanoplatelets, demonstrated a viability loss of up to 
69.5 %, as opposed to the control with no graphite nanoplatelets.44 Work in our laboratories has 
demonstrated that following minimal bactericidal concentration assays using particulate compounds, 
when tested against Gram negative Escherichia coli, graphite demonstrated greater antimicrobial 
efficacy than graphene and was comparable with the antimicrobial efficacy of zinc oxide (Fig.1). 
However against Gram positive S. aureus, although graphite again demonstrated greater antimicrobial 
activity than graphene, its antimicrobial efficacy was not greater than that of zinc oxide. This may be 
explained in part due to the differences in the chemical composition of bacterial cell walls of Gram 
negative and Gram positive bacteria.  
 
 
Fig. 1. Minimal bactericidal concentrations (MBC) of graphite, graphene oxide and zinc oxide 
demonstrating that the graphite demonstrates antimicrobial efficacy against E. coli and S. aureus (Work 
courtesy of Daniel Brown, MMU, UK). 
 
The use of graphite as an antimicrobial surface coating is in its infancy, however, early results 
using carbon thin films have been promising.45 In a study whereby carbon thin films (previously known 
as graphite) were used as a antimicrobial coatings on a polyethylene terephthalate (PET) surface, the 
results demonstrated that the carbon thin films reduced bacterial adherence capabilities by 65 % and 86 
% for both S. aureus and Staphylococcus epidermidis, respectively.45  
Shteynle, (2012) compared the absorbency and fluid retention of two variants of nanostructured 
graphite wound dressings and a variety of “gold standard” wound dressings. The nanostructured 
graphite wound dressings demonstrated the greatest adsorption potential, but no antimicrobial testing 
was carried out. The nanostructured graphite wound dressings were able to adsorb the wound exudate 
due to a variety of mechanisms including covalent bonding, a system of numerous interweaving fibres 
that produced a high surface area46, and a matrix consisting of strong fluoride oxidisers, resulting in 
large quantities of free radicals. Furthermore, these oxidisers added oxygenated species to the surface 
of the graphite, increasing its hydrophobicity.47 It has been reported that the absence of excessive wound 
exudate (i.e. by adsorption), can reduce the risk of nosocomial/opportunistic infection by making the 
conditions for the commensal microflora less than favourable.48 Graphite is proposed to be able to act 
as an antimicrobial in a variety of ways, including physiochemical responses leading to membrane 
 
stress, sharp nanosheets which result in disruption of the cell membrane and via the production of 
reactive oxygen species, due to the oxidation of glutathione which acts as a redox mediator in bacterial 
cells.49  
Graphite oxide 
Graphite oxide is produced via the oxidation of natural graphite. Characterisation studies identify 
graphite oxide as a lamellar solid containing phenolic, carboxyl and epoxide groups. This makes 
graphite oxide hydrophilic, with the production of monolayer colloidal dispersions upon interaction 
with water.50 Delamination of graphite oxide solids often forms the basis for the synthesis of graphite 
oxide nanomaterials. Graphite oxide has unique properties, namely enhanced electrochemical activities 
in the form of capacitor materials due to the presence of hydroxyl, epoxy and carbonyl groups 51, 52, 53. 
Graphite oxide is often only ever intended to be used as a by-product in the synthesis of graphene-based 
nanosheets produced by the chemical reduction of exfoliated graphite oxide and the antimicrobial 
efficacy of graphite oxide has yet to be fully documented. However, in one study54, the antimicrobial 
efficacy of graphite oxide was compared to that of other carbon-based materials (graphite, graphene 
oxide and reduced graphene oxide) against E. coli. The results showed that graphene oxide had the 
greatest antimicrobial activity (inactivating 69 % of bacterial cells after 2 hours of incubation) followed 
by reduced graphene oxide, graphite followed by graphite oxide which inactivated 15 % of bacterial 
cells at the same dispersion concentration.54 Das et al, (2011) synthesised a silver nanoparticle and 
graphite oxide nanosheet composite. Using X-ray diffraction and transmission electron microscopy, the 
results indicated that the silver nanoparticles decorated the graphite oxide sheets and following 
antimicrobial testing of the nanosheets, antibacterial activity was indicated against E. coli and P. 
aeruginosa using zone of inhibition assys.20 The underlying antimicrobial mechanism of graphite oxide 
remains unclear, however its large surface area could allow for cell wrapping. Cell wrapping can be 
attributed to the hydrophobicity of graphene materials, since the graphene sheets are hydrophobic. This 
can lead to the phospholipid bilayers of microorganisms (in direct contact with the graphene) to become 
inversed, therefore leading to the loss of membrane integrity and cell lysis55. Other antimicrobial 
mechanisms for graphite oxide include its oxygen containing surface functionalities such as carboxylic, 
 
carbonyl, hydroxyl and epoxide groups as well as its increased water solubility which provides a basis 
for ion or nanoparticle intercalation, which can in turn have a detrimental effect on bacterial cells.56 
Reduced Graphite Oxide 
Reduced graphite oxide is often used as a starting product in the production of graphene. Graphite oxide 
is reduced by a two-step system, with the first step being the removal of oxygen groups via the use of 
sodium tetrahydridoborate followed by the second step which uses concentrated sulphuric acid 
to dehydrate and therefore restore the chemical structure57. Research into reduced graphite oxide as a 
standalone material is relatively novel, however due to its reported unique electrochemical properties 
(as demonstrated by all graphene-based materials), an increasing amount of research has been recently 
targeted in this area – especially with the application of reduced graphite oxide as a material for use in 
supercapacitors and batteries.58, 59 However research into the antimicrobial efficacy has not yet been 
fully elucidated. 
In 2011, Dai et al., produced a novel reduced graphite oxide-silver nanocomposite which showed a 
synergistic antimicrobial effect. The reduced graphite alone displayed no apparent antimicrobial effect 
however, when used in combination with silver ions an improved synergistic antimicrobial effect was 
seen.60 The authors hypothesized that the reduced graphite oxide acted as a supporting structure, whilst 
the silver ions possessed the overall antimicrobial ability.60 This was emphasised by Gerasymchuk et 
al., (2016) who carried out antimicrobial testing on a reduced graphite oxide, silver nanoparticle and 
bis(lysinato)zirconium(IV) phthalocyanine complexes.61 The complex was tested for its antimicrobial 
efficacy against S. aureus, E. coli and P. aeruginosa. The results showed a prolonged synergistic 
antimicrobial effect after near-infrared irradiation, with a four-fold decrease observed in the Gram-
negative strains (P. aeruginosa and E. coli) viable cells.61 The authors suggested that the complex 
should be tested as an antimicrobial surface coating for use in the field of dentistry or as a wound 
dressing due to its long lasting properties61. Therefore, the use of reduced graphite oxide in combination 
with another antimicrobial agent could potentially demonstrate a synergistically antimicrobial effect. 
Graphene 
Since the discovery of graphene by Geim and Novoselov in 2006/7, research into this material 
and field has increased exponentially62. Graphene is a one-layer atom thick sheet of hexagonally 
 
arranged carbon. In recent years, graphene has attracted a lot of interest in a wide variety of industries, 
due to its unique properties such as excellent thermal conductivity (up to 5,000 W m−1 K−1), electrical 
conductivity, high electron mobility of up to 200,000 cm2 V-1 s-1, permeability to gases, excellent tensile 
strength (42 N m−1), and its high surface area (2630 m2 g-1)63. Graphene has a variety of proposed 
antimicrobial mechanisms including damage due to physiochemical interactions (hydrophobicity), or 
due to physical interactions (size / sharp edges) (Fig. 2). The lateral size of graphene-materials is 
essential when determining the antimicrobial activity, this is because lateral size can influence the 
adsorption, dispersibility and the structure, including sharp edges – which are crucial for antimicrobial 
physiochemical interactions between the graphene-materials and microorganisms. 
 
Fig. 2. Schematic illustration of the potential mechanisms of antibacterial activity of the graphites / 
graphenes (Microbial figure courtesy of Dr Lucia Cabellero, MMU, UK). 
 
 
Another proposed antimicrobial action proposed to be demonstrated by larger molecules of 
graphene materials is cell wrapping64. Dallavalle et al., (2015) investigated the relationship between 
graphene material lateral size and antimicrobial mechanisms65. It was demonstrated that graphene 
material, less than 5.2 nm in size, had a predominant physical effect against microorganisms leading to 
cell lysis by protrusion of cell membranes, which is in turn attributed to the sharp edges of graphene 
materials.65 On the other hand, larger graphene molecules (more than 5.2 nm) act by reducing the 
microbial activity / cell viability of bacterial microorganisms through “wrapping” process, without 
affecting the cell’s integrity / shape. This was demonstrated by measuring nicotinamide adenine 
dinucleotide hydrogen and/or nicotinamide adenine dinucleotide phosphate, in a cellular metabolic 
assay30. 
Large area monolayer graphene foams, have been used as a surface coating of copper 
conductors, and demonstrated promising properties against both Staphylococcus aureus and 
Escherichia coli. However, when the same bacteria were tested on a graphene-coated silicon dioxide 
insulator, although antimicrobial activity was observed, the morphology of the bacteria remained the 
same, therefore, charge transfer may be another mechanism of antimicrobial activity.66 This charge 
transfer mechanism was described in further detail by Bykkam et al., (2015) which showed graphene 
foams coated with zinc oxide nanoparticles irradiated high photon energy levels, leading to the transfer 
of electrons from the valence band to the conduction band of the product material. This was shown to 
produce holes in the valence band, which were able to react with hydroxyl groups and absorbed water 
to create hydroxyl radicals (-OH). Electrons trapped in the conduction band by the presence of oxygen 
were shown to produce superoxide radical ions (O-2), whilst hydrogen peroxide was generated by the 
combination of the electron pair hole, the production of reactive oxygen species (ROS) then exhibited 
a detrimental effect on the bacterial cells67.  
Akhavan and Ghaderi, (2010), investigated the antimicrobial activity of graphene layers against 
both Gram positive (S. aureus) and Gram negative bacteria (E. coli), however the results demonstrated 
a greater antimicrobial effect against S. aureus, possibly due to lack of an outer membrane68. However, 
antimicrobial activity was also demonstrated when zinc nanoparticles were imbedded into graphene 
sheets producing zones of inhibition against Gram negative Salmonella typhi and Gram negative E. 
 
coli69 In one study, a novel graphene based silver/ hydroxyapatite / graphene (Ag / HAP / Gr) composite 
surface coating was produced by electrophoretic deposition (EPD), and the antimicrobial efficacy was 
tested against both S. aureus and E. coli. The results showed that after one hour bacterial growth had 
been inhibited by 72.9 % and 68.4 %, respectively, and after 24 the samples did not contain any viable 
cells, thus suggesting that the antimicrobial activity was effective against both  planktonic and biofilm-
forming strains of bacteria70. Due to graphene’s low cytotoxic activity against human cells and excellent 
bacterial toxicity, it is an ideal candidate for application with biomaterials. When graphene was used as 
a surface coating of poly(N-vinylcarbazole) (PVK), results showed inhibition of up to 80 % of biofilm 
growth, after 24 hour of incubation with E. coli and Bacillus subtilis, compared against a NIH 3T3 
(mouse) cell line where over 80 % of the cells were viable after 24 hours.71 In our laboratories, when 
3D graphene foams have been combined with metal ions, using zone of inhibition assays, antimicrobial 
activity was demonstrated to be increased against Gram positive bacteria (Fig. 3).  
 
Fig. 3. Antimicrobial activity of few layer 3D freestanding graphene foams doped with metals  
 
Antibacterial activity was also demonstrated against the more recalcitrant Gram negative Klebsiella 
pneumoniae and Acinetobacter baumannii. Further, our work demonstrated that on a 3D graphene foam 
substrate that has been soaked in a gallium compound, the physiological structure of the bacterial cells 




























Fig. 4. a) Enterococcus faecium cell structure b) Enterococcus faecium following inoculation onto a 3D 
graphene / gallium structure (Images courtesy Anthony Slate and Dr Grace Crowther, MMU, UK). 
 
Therefore, with further research, graphene could have the potential to be used as a surface 
coating for both equipment (i.e. nosocomial setting) and/or in wound dressings, due to its variety of 
antimicrobial mechanisms, including physiochemical interactions such as cell wall penetration, and cell 
wrapping depending on the lateral size of the graphene particle.  
Graphene Oxide 
Much alike graphene, graphene oxide is a 2D-nanomaterial with promising applications in a variety of 
fields including polymer composites, electrochemical appliances (i.e. electrodes), sensors and 
biomedical applications9 due to its excellent electrical, thermal and mechanical properties12. Unlike 
graphene, graphene oxide is hydrophilic due to the oxygen containing groups, allowing it to solubilise 
in water.10 Graphene oxide is a promising material for the development of antimicrobial surface coating, 
due to its reported excellent contact-based antimicrobial activity; however the exact mechanisms are 
yet to be fully elucidated.11 Graphene oxide is reported to have demonstrated broad-spectrum 
antimicrobial activity against both bacteria and fungi, including resistant strains.13 Graphene oxide has 
also demonstrated broad spectrum antiviral activity; it was shown to significantly reduce both 
pseudorabies virus (PRV) and porcine epidemic diarrhoea virus (PEDV), leading to a two log reduction 
of viral titres.72 This antimicrobial activity has been attributed to the introduction of oxygen-containing 
groups present in graphene oxide. It has been shown that altering the surface properties of graphene 
oxide, such as the edge planes, can dramatically improve antimicrobial activity, leading to a marked 
 
improvement in both amphipathy (important for the wrapping mechanism) and physiochemical 
effects.68   
Since graphene oxide is water-soluble it has properties that allow for high drug loading and 
miscibility with polymers, effectively allowing it to be moulded into any desired shap14. Bitounis et al., 
(2013) reported that in a study investigating the antimicrobial effect of graphene based materials, that 
graphene oxide demonstrated the greatest antimicrobial efficacy followed by reduced graphene oxide, 
and this was suggested to be due to the production of ROS which led to oxidative stress, leading to 
more severe membrane damage and therefore loss of cell membrane integrity73.  
A decrease in graphene oxide sheet size (0.65 μm2 to 0.01 μm2), when tested against E. coli, 
also demonstrated a direct correlation of increased antimicrobial activity, due to physiochemical 
interactions11. In contrast, when using a suspension assay, the larger the graphene oxide sheets, the more 
effective became the antimicrobial activity. This was suggested to be due to cell entrapment, i.e. 
wrapping, with complete inactivation observed with the 0.65 μm2 graphene oxide sheets after 3 hours 
of exposure. However cell inactivation due to the cell entrapment mechanism could be reversed, when 
separating the graphene oxide sheets by sonication.11 Graphene oxide nanosheets have demonstrated 
strong antimicrobial properties when used in conjunction with thin-film composites as a surface coating. 
Graphene oxide nanosheets were irreversible attached via amide coupling of carboxyl groups present 
on both graphene oxide and a polyamide active layer. Microbiological testing of this surface coating 
against E. coli showed 65 % bacterial inactivation after 1 hour of incubation74. In another study, a 
graphene oxide-iron oxide nanoparticle-silver nanoparticle (GO-IONP-Ag) complex was evaluated as 
a surface coating. The results showed that the composite was more effective than silver nanoparticles 
alone, showing a marked increase in antimicrobial activity against both Gram-positive (S. aureus) and 
Gram-negative (E. coli) bacterial strains. This synergistic ability was thought to be due to light being 
absorbed by the GO demonstrated a synergistic response, resulting in the photo-thermal killing of the 
bacteria75. Faria et al., (2014) also used graphene oxide in combination with silver nanoparticles as a 
surface coating, which resulted in 100 % growth inhibition of Pseudomonas aeruginosa, with a 
minimum inhibitory concentration (MIC) ranging between 2.5 – 5.0 mg/L76. Work by Whitehead et al., 
(2017) has demonstrated that when silver-graphene oxide (AgGO) or zincoxide-graphene oxide 
 
(ZnOGO) complexes were tested for their antimicrobial activity against four prominent bacteria which 
have all demonstrated increased multidrug resistance (E. coli, Methicillin Resistant S. aureus (MRSA), 
Enterococcus faecium and Klebsiella pneumoniae) that AgGO was the most effective antimicrobial. 
The addition of Ag enhanced the activity of GO against the bacteria tested, including the generally 
recalcitrant K. pneumoniae and Enterococcus faecium. Zhao et al., (2016) developed a gelatin-
functionised graphene oxide coating which was impregnated onto a nitinol substrate. The results 
showed both strong antimicrobial activity against E. coli and excellent biocompatibility26. Therefore it 
can be evidenced that alterations to the graphene oxides surface properties as well as its characteristic 
functional groups (leading to the production of ROS) allows graphene oxide to interact with 
microorganisms in a dual approach, therefore suggesting an explanation towards the prolific 
antimicrobial activity demonstrated. 
Reduced Graphene Oxide 
In order to obtain reduced graphene oxide (also known as functionalised graphene or reduced graphene), 
removal of oxygen-containing groups is vital, with the end goal of the reduction protocol being to 
produce graphene-like materials with similar properties to graphene77. Reduction of graphene oxide can 
be undertaken by a variety of mechanisms including, mechanical / thermal exfoliation, epitaxial growth 
and chemical vapour deposition.78, 79  
Reduced graphene oxide has demonstrated a vast array of potential applications including 
electrochemical materials,15 photocatalysis,80 industrial lubricants and corrosion protection.81 The 
antimicrobial activity of graphene oxide has yet to be fully elucidated, however, studies so far have 
demonstrated positive results with the potential application of reduced graphene oxide to be used as a 
viable antimicrobial agent.79 In one study, a biocompatible reduced graphene oxide-silver nano-hybrid 
was prepared and tested as an antimicrobial topical agent i.e. as a surface coating for dressings and 
bandages. The results found that excellent cytocompatibility was observed towards peripheral blood 
mononuclear cells and mammalian red blood cells whilst antimicrobial assays against S. aureus, E. coli 
and Candida albicans showed synergistic antimicrobial activity compared to reduced graphene oxide 
and silver nanoparticles as individual antimicrobial therapies82. This biocompatibility of reduced 
graphene oxide has also been described when used in combination with calcium silicate which plays an 
 
important role in bone tissue engineering. The use of a calcium silicate and reduced graphene oxide 
composite increased the fracture toughness by 123 % without negatively effecting the attachment of 
human osteoblast cells (hFOB)83.  
Synergistic antibacterial activity has been demonstrated between reduced graphene oxide and 
boron-doped diamond anodes, with the results showing a reduction of 0.7 log of E. coli after 20 min of 
incubation with graphene oxide. However, 100 % inactivation of E. coli growth was demonstrated when 
reduced graphene oxide was tested in combination with a three dimensional electrochemical system79. 
Previous studies proved that hydroxyl radicals played a pivotal role in boron doped diamond 
electrochemical disinfection, and it was hypothesised that the reduced graphene oxide led to an 
expansion in the electrode area and therefore generated more hydroxyl radicals84. Reduced graphene 
oxide nanosheets doped onto titanium dioxide thin films showed improved antimicrobial activity 
against E. coli under solar light radiation (by 60 %) after 0.5 hours. The thin films were demonstrated 
to be chemically stable and it was suggested that they could be used as an antimicrobial surface coating 
for hospital equipment, thus potentially reducing the transmission of AMR and other microorganisms.85 
Evidence suggests that the main mechanism of antimicrobial activity produced by reduced graphene 
oxide is due to the production of reactive oxygen species. This was shown to be the case in one study, 
where the exposure of graphene oxide and reduced graphene oxide to P. aeruginosa induced significant 
amounts of superoxide radical anions, leading to the loss of cell viability.16  
Non-carbon based 2D nanomaterials 
Other non-carbon based, 2D-nanomaterials with potential applications in antimicrobial surface coatings 
include boron nitrite, tungsten dioxide and molybdenum disulphide. However, these surfaces have not 
been investigated in great depth for their antimicrobial activity.  
Boron Nitride 
Boron nitride commonly exists in a layered structure of hexagonal honeycombs comprised of 
equal amounts of boron and nitrogen atoms. These layers are held together by van der Waals forces, 
with the nitrogen atoms directly above the boron atoms.17 Due to its similarity to graphene, both in 
terms of structure and properties it is often referred to as “white graphene” 86. This similarity has been 
observed by a number of studies, with one example being the use of boron nitride as a electrochemical 
 
dopamine biosensor.87 In recent years, research with boron nitride has shown antimicrobial activity 
related to the 2D-nanomaterial. It was demonstrated that aqueous dispersions of boron nitride nanotubes 
exhibited little antimicrobial activity against E. coli and S. aureus. However, when coated in 
combination with polyethyleneimine, the boron nitride nanotubes exhibited a significant synergistic 
antimicrobial activity against E. coli and S. aureus, with the authors suggesting the potential application 
of boron nitride nanotubes as surface coatings for use in water purification and food packaging 
systems.88  
Tungsten Diselenide 
Another 2D-nanomaterial with great potential is tungsten diselenide (Se2W). When in crystalline 
monolayers it is found to act as a promising emitter of light at around 750 nm.89 Tungsten diselenide is 
a two dimensional metal dishalcogenide, with a semiconducting nature.90 These properties allow WSe2 
to act as a photo-catalyst, leading to the production of hydrogen, which result in the generation of ROS 
which have the ability to cause damage to a wide array of microorganisms by a variety of mechanisms. 
91,92 The research into the antimicrobial effect of tungsten diselenide is in its infancy, however recent 
studies have demonstrated impressive antimicrobial efficacy.90,93 One study demonstrated the 
antimicrobial activity of selenium nanoparticles when used as a surface coasting in conjunction with 
polymeric medical devices.94 In another study, tungsten diselenide in combination with single-stranded 
DNA (ssDNA) and the antimicrobial efficacy of the WSe2-ssDNA nanosheets was evaluated against E. 
coli. The results demonstrated a greater antimicrobial effect compared to the use of graphene oxide.93 
Research into Se2W may show potential for this to be developed into an alternative antimicrobial 
surface coating.95  
Molybdenum Disulfide  
Molybdenum disulphide (MoS2) which is also a two dimensional metal dishalcogenide, is the principle 
natural source of molybdenum, and is mainly obtained as a secondary product from the mining of 
copper. Anisotropic properties of MoS2 which arise due to its laminar nature (similar to graphite), allow 
MoS2 to be used in a variety of applications including industrial lubricants, catalysts and electrical 
energy storage products.18  
 
The antimicrobial efficacy of 2D chemically exfoliated MoS2 sheets was evaluated by Yang et 
al., (2014) against E. coli. The results demonstrated that an MIC of 2.5 g / mL was inhibitory to the 
bacteria and this antimicrobial activity was attributed to the production of ROS, particularly due to 
glutathione oxidation which showed a time and concentration dependent trend. It was speculated that 
the accumulation of ROS led to both membrane and oxidative stress, and eventually loss of cell 
membrane integrity and death96. It has been further suggested that the MoS2 showed a greater amount 
of antimicrobial activity towards Gram-positive bacteria.97,98 In agreement with this, work in our 
laboratories has demonstrated that molybdenum disulphide surfaces do have some antimicrobial 
activity against Gram positive (S. aureus) and Gram negative (E.coli) biofilms (Fig. 5). Biofilm 
inhibition has also been demonstrated by molybdenum disulphide by others. In a study, P. aeruginosa 
biofilms were grown with molybdenum disulphide at a concentration of 150 g / mL and the results 
showed a decrease in the biofilm growth of up to 40 %, in addition to shrinkage in biofilm depth after 
treatment89. These results may prove to be extremely important given the recalcitrant nature of biofilms.  
 
 
Fig. 5. Antimicrobial effect of MoS2 surfaces evaluated against biofilms (Work courtesy of Moshin 




Throughout this chapter, the antimicrobial potential and applications for the use of 2D-nanomaterials, 
especially in the case of potential antimicrobial surface coatings has been discussed. Although research 
into 2D-nanomaterials as surface coatings is in its infancy, research in this area is rapidly progressing. 
However, more research is needed in order to fully elucidate and characterise all the mechanisms of 
antimicrobial activity of such materials. This would allow researchers to be able to modify the 
nanomaterials structures / properties in order to make them more potent and effective as antimicrobial 
agents. In addition to using these 2D nanomaterials as stand-alone antimicrobial interventions, there is 
significant interest in utilising these 2D nanomaterials in combinations with other molecules, functional 
groups and metals. Combinations of such chemical moieties may result in surfaces that demonstrate 
synergistic antimicrobial effects, that may have the potential to reduce the transmission of nosocomial 
infections. This in turn may decrease the current burden which is currently placed upon conventional 
bacterial treatments such as antibiotics. The current literature highlights the huge potential these 
nanomaterials could have in order to reduce the transmission of antimicrobial resistant bacteria. 
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